DALLAS, TX - Aug 20, 2025 - Sonara Health, a hybrid care platform revolutionizing methadone treatment for opioid use disorder (OUD), today announced the closing of a $15 million Series A funding round. Led by B Capital, with participation from FirstMark Capital, Sonara aims to enhance access and adherence to life-saving addiction treatment. Founded by Michael Giles, MD, Sonara’s platform integrates in-person and virtual care to address the opioid crisis.
“This funding will transform how we deliver methadone treatment, making it more accessible and effective for patients,” said Dr. Giles.
B Capital’s General Partner stated, “Sonara’s innovative approach to addiction care is critical in tackling a pressing public health challenge.” The capital will drive platform enhancements and nationwide expansion, positioning Sonara as a leader in addiction treatment.
Funding Details
Sonara Health raised $15 million in its Series A funding round, led by B Capital, a venture capital firm focused on transformative healthcare technologies. FirstMark Capital also participated, reflecting strong investor confidence in Sonara’s hybrid care model. The all-equity round will support the expansion of Sonara’s platform and its mission to improve outcomes for OUD patients.
Strategic Goals and Use of Funds
Sonara Health will deploy the $15 million to achieve the following strategic objectives:
- Platform Enhancement: Advance its AI-powered platform with improved telehealth, compliance tracking, and patient engagement tools.
- Nationwide Expansion: Scale operations to additional states, targeting 50 new clinics by 2027 to increase access to methadone treatment.
- Team Growth: Expand clinical, engineering, and patient support teams to enhance service delivery and platform scalability.
- Provider Partnerships: Develop partnerships with opioid treatment programs (OTPs) and healthcare providers to integrate Sonara’s platform into existing care systems.
- Patient Support Programs: Invest in AI-driven adherence tools and patient education to improve treatment outcomes and retention rates.
Historical Funding and Growth
Sonara Health has raised capital to support its growth in addiction treatment. Below is a summary of its funding history:
| Round | Year | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Seed | 2023 | Not disclosed | Not disclosed | Not disclosed |
| Series A | 2025 | $15M | Not disclosed | B Capital |
Founded in 2022, Sonara Health has grown to serve multiple opioid treatment programs across the U.S., with early data showing a 40% improvement in treatment adherence among patients using its platform. The company has partnered with clinics to deliver hybrid care, addressing barriers to methadone access.
Sonara Health’s Platform
Sonara Health’s platform integrates in-person and virtual tools to enhance methadone treatment for OUD. Leveraging AI, the platform offers remote dosing verification, telehealth consultations, and real-time compliance monitoring. Key features include a mobile app for patient-provider communication, AI-driven adherence analytics, and integration with clinic workflows, ensuring safe and effective treatment delivery. The platform reduces barriers like transportation and stigma, enabling patients to access care conveniently while maintaining regulatory compliance.
Industry Impact and Challenges
Sonara Health is transforming addiction treatment by improving access to methadone, a proven therapy for OUD, amid a crisis affecting over 2.5 million Americans. Its hybrid model has increased patient retention and reduced relapse rates in pilot programs. Challenges include navigating complex regulatory requirements for methadone dispensing, ensuring data privacy under HIPAA, and competing with traditional in-person clinics and emerging telehealth platforms. Scaling partnerships with OTPs while maintaining care quality is also critical.
Market Context and Industry Trends
The $15 million Series A round aligns with the growing digital health market, projected to reach $300 billion by 2028, driven by demand for telehealth and AI-driven care solutions. Recent investments, such as $250 million for EliseAI and $8.6 million for Cascala Health, highlight strong interest in healthcare technology. Sonara’s focus on hybrid care for OUD positions it to address the opioid crisis, leveraging trends toward telehealth adoption and personalized treatment in behavioral health.
Stakeholder Perspectives
- Michael Giles, MD, Founder & CEO of Sonara Health: “Our platform is breaking down barriers to methadone treatment, and this funding will help us reach more patients in need of effective care.”
- B Capital Representative: “Sonara’s hybrid care model is a game-changer for addiction treatment, addressing a critical public health need with innovative technology.”
Stakeholder Insights
Investors view Sonara Health as a leader in addiction treatment, with its platform addressing critical gaps in access and adherence. The participation of B Capital and FirstMark Capital signals confidence in Sonara’s potential to scale and impact the opioid crisis. Analysts note that success will depend on securing partnerships with OTPs and demonstrating sustained improvements in patient outcomes, positioning Sonara to compete in the evolving behavioral health market.
About Sonara Health
Founded in 2022 by Michael Giles, MD, Sonara Health is a Dallas-based healthcare technology company revolutionizing methadone treatment for opioid use disorder. Its hybrid care platform integrates in-person and virtual tools, leveraging AI to enhance access, adherence, and outcomes. Backed by B Capital and FirstMark Capital, Sonara serves opioid treatment programs nationwide and is headquartered in Dallas, Texas.
Future Outlook
Sonara Health is poised to lead the transformation of addiction treatment, leveraging its $15 million Series A to expand its platform and reach. The company aims to partner with 50 new clinics by 2027 and achieve a 50% improvement in treatment adherence across its network. By advancing AI-driven tools and provider partnerships, Sonara seeks to address the opioid crisis and capture a significant share of the digital health market.
Media Contact
For more information, please contact:
Email: press@sonarahealth.com
Website: www.sonarahealth.com
